{
  "title": "Fewer COVID Vaccine Doses Materialized Last Fall Than The U.S. Government Hoped",
  "description": "Manufacturers can expect to face unforeseen hurdles when they begin to mass-produce a brand new pharmaceutical product, and in a pandemic, there are bound to be supply chain problems as well. But in late 2020, Pfizer was delivering fewer doses than the government expected and then-federal officials told NPR they did not know why. ",
  "pubDate": "Wed, 08 Sep 2021 00:10:00 -0400",
  "copyright": "Copyright 2019-2021 NPR - For Personal Use Only",
  "guid": "64d99e54-237b-49e8-96f4-655533efcee9",
  "link": "https://www.npr.org/2021/09/02/1033612000/fewer-covid-vaccine-doses-materialized-last-fall-than-the-u-s-government-hoped",
  "itunes:title": "Fewer COVID Vaccine Doses Materialized Last Fall Than The U.S. Government Hoped",
  "itunes:episode": 480,
  "itunes:author": "NPR",
  "itunes:summary": "Manufacturers can expect to face unforeseen hurdles when they begin to mass-produce a brand new pharmaceutical product, and in a pandemic, there are bound to be supply chain problems as well. But in late 2020, Pfizer was delivering fewer doses than the government expected and then-federal officials told NPR they did not know why. ",
  "itunes:image": "",
  "itunes:duration": 775,
  "itunes:explicit": "no",
  "itunes:episodeType": "full",
  "content:encoded": "Manufacturers can expect to face unforeseen hurdles when they begin to mass-produce a brand new pharmaceutical product, and in a pandemic, there are bound to be supply chain problems as well. But in late 2020, Pfizer was delivering fewer doses than the government expected and then-federal officials told NPR they did not know why. ",
  "enclosure": ""
}